{"product_id":"omic-vrio-analysis","title":"Singular Genomics Systems, Inc. (OMIC): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlocking the secrets to Singular Genomics Systems, Inc. (OMIC)'s long-term success starts here: our rigorous VRIO analysis distills whether its core assets truly deliver sustainable competitive advantage through Value, Rarity, Inimitability, and Organization. Discover the critical strengths - and potential weaknesses - that define Singular Genomics Systems, Inc. (OMIC)'s market position by reading the full breakdown below.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSingular Genomics Systems, Inc. (OMIC) - VRIO Analysis: 1. Proprietary Sequencing Engine Chemistry (Core IP)\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at the engine room of Singular Genomics Systems, Inc., especially now that the company is private under Deerfield Management as of \u003cstrong\u003eFebruary 2025\u003c\/strong\u003e. This proprietary sequencing chemistry is what separates their G4 and G4X platforms from the pack. It’s not just a feature; it’s the foundation for their spatial multiomics push.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Core Tenets of Performance\u003c\/h3\u003e\n\u003cp\u003eThe value here is direct: better output quality and higher capacity from the same instrument footprint. This novel chemistry, which includes unique enzymes and synthesized dyes, directly enables the platform’s core promises of accuracy, speed, and flexibility. For instance, the commercially available G4 Sequencing Platform is already hitting benchmarks where over \u003cstrong\u003e90%\u003c\/strong\u003e of bases achieve a quality score of Q30 or better. This level of reliability is non-negotiable for translational research.\u003c\/p\u003e\n\u003cp\u003eThe G4X Spatial Sequencer, which began initial shipments in \u003cstrong\u003eJune 2025\u003c\/strong\u003e, leverages this chemistry for in situ sequencing, meaning the nucleic acids stay put in the tissue. This capability allows for unprecedented data density. Here’s the quick math on what that chemistry enables on the G4X:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSpatial sequencing cost reduced \u003cstrong\u003e5-fold\u003c\/strong\u003e, from about $1,700 to \u003cstrong\u003e$240\u003c\/strong\u003e per sample at scale.\u003c\/li\u003e\n\u003cli\u003eAbility to profile \u003cstrong\u003e500-Plex\u003c\/strong\u003e Spatial Transcriptomics and \u003cstrong\u003e18-Plex\u003c\/strong\u003e Spatial Proteomics in one run.\u003c\/li\u003e\n\u003cli\u003eProcessing up to \u003cstrong\u003e128 samples\u003c\/strong\u003e per run on an X4 flow cell.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eRarity: Beyond Off-the-Shelf Components\u003c\/h3\u003e\n\u003cp\u003eYes, this is rare. The search results confirm that Singular Genomics developed a new and proprietary sequencing chemistry, specifically designing novel compounds, polymers, enzymes, and dyes to optimize performance. This isn't just tweaking existing reagents; it’s building the core chemical reaction from the ground up. This unique combination of chemical components and the Direct-Seq method for in situ sequencing is not standard, off-the-shelf technology available to competitors.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: The R\u0026amp;D Moat\u003c\/h3\u003e\n\u003cp\u003eHonestly, copying this is defintely difficult. Replicating novel, highly optimized chemistry requires significant, sustained Research and Development investment and years of iterative testing. It’s not something a competitor can just license or buy quickly. The complexity of integrating novel enzymes with their proprietary imaging system means that imitation requires replicating not just the chemical formula but the entire engineering ecosystem built around it. What this estimate hides is the institutional knowledge gained over years of failed experiments.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: Pipeline Integration\u003c\/h3\u003e\n\u003cp\u003eThe organization shows a clear commitment to this IP. The entire product pipeline, from the established G4 to the newly commercialized G4X Spatial Sequencer, is explicitly built upon this Sequencing Engine. The G4X is designed to be a dual-purpose instrument for both traditional Next-Generation Sequencing (NGS) and spatial multiomics, showing tight integration of the core chemistry across their entire offering. This tight coupling means the value of the chemistry is realized across their entire product portfolio.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage: Sustained Protection\u003c\/h3\u003e\n\u003cp\u003eThe competitive advantage here is \u003cstrong\u003eSustained\u003c\/strong\u003e. Because the chemistry is foundational, rare, and difficult to copy, it acts as a deep moat protecting their performance claims in high-throughput and spatial analysis. This IP underpins their ability to deliver the high throughput and cost-efficiency that researchers need to scale studies, which is a critical differentiator against established players in the genomics space.\u003c\/p\u003e\n\n\u003cp\u003eHere is a quick look at the performance metrics directly tied to this core chemistry:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric Driven by Core Chemistry\u003c\/td\u003e\n\u003ctd\u003ePlatform\u003c\/td\u003e\n\u003ctd\u003eValue\/Specification (2025 Data)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBase Quality (Q Score)\u003c\/td\u003e\n\u003ctd\u003eG4 Sequencing Platform\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e90%\u003c\/strong\u003e of bases at Q30 or higher\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpatial Sample Throughput (Max)\u003c\/td\u003e\n\u003ctd\u003eG4X Spatial Sequencer\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e128 samples\u003c\/strong\u003e per run\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpatial Multiomic Scale (Single Cell)\u003c\/td\u003e\n\u003ctd\u003eG4X Spatial Sequencer (X2 Flow Cell)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e6.2 million cells\u003c\/strong\u003e and \u003cstrong\u003e438 million transcripts\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost Per Spatial Sample (Scaled)\u003c\/td\u003e\n\u003ctd\u003eG4X Spatial Sequencer\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$240\u003c\/strong\u003e (down from $1,700)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSingular Genomics Systems, Inc. (OMIC) - VRIO Analysis: 2. G4X™ Spatial Sequencer Technology\n\u003c\/h2\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eOpens up the high-growth spatial multiomics market, allowing simultaneous measurement of transcripts, proteins, and H\u0026amp;E in tissue context. The platform offers multiomic FFPE Analysis: high-resolution analysis of transcriptomics, proteomics, and fluorescent H\u0026amp;E simultaneously on the same FFPE sample. The system enables spatial biology at an unprecedented scale with an expansive imaging area of \u003cstrong\u003e40 cm\u003csup\u003e2\u003c\/sup\u003e\u003c\/strong\u003e per run across \u003cstrong\u003e4\u003c\/strong\u003e independent spatial flow cells.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eData Point\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMaximum Reads\/Day\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1.6 B\u003c\/strong\u003e reads\/day\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMaximum Output\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e480 Gb\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRun Time\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e12\u003c\/strong\u003e to \u003cstrong\u003e24 hours\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSample Throughput (Max)\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e128\u003c\/strong\u003e samples per run\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e3D Reconstruction Scale Example\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e10\u003c\/strong\u003e serial sections, \u003cstrong\u003e6.2 million\u003c\/strong\u003e cells, \u003cstrong\u003e438 million\u003c\/strong\u003e transcripts from a single flow cell\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eYes. The combination of high throughput with spatial multiomics on a single platform is rare as of mid-2025. The platform is positioned to be the only company worldwide to offer capabilities for tissue-based \u003cstrong\u003ein situ spatial multiomics and NGS on the same instrument\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eTemporary. Competitors are racing to match spatial capabilities, but the demonstrated 3D reconstruction is a current lead. The platform supports:\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eSingle-day sequencing powered by rapid imaging and novel high-speed chemistry.\u003c\/li\u003e\n\u003cli\u003eDirect-Seq: In situ sequencing of RNA.\u003c\/li\u003e\n\u003cli\u003eAnalysis of hundreds of gene transcripts and dozens of proteins.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eYes. The ongoing Early Access Program and on-track \u003cstrong\u003eJune 2025\u003c\/strong\u003e shipments show effective execution of the launch plan.\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eEarly Access Program ongoing, with plans to expand to more sites in \u003cstrong\u003eQ2\u003c\/strong\u003e (2025).\u003c\/li\u003e\n\u003cli\u003eInitial shipments on track for \u003cstrong\u003eJune 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company reported a cash position of \u003cstrong\u003e$150.7 million\u003c\/strong\u003e as of March 31, 2024.\u003c\/li\u003e\n\u003cli\u003eLong-term lease obligations were reduced by approximately \u003cstrong\u003e$50 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eTemporary. It’s a first-mover advantage in this specific high-throughput spatial niche. The G4X is expected to offer a strong value proposition and higher margins.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSingular Genomics Systems, Inc. (OMIC) - VRIO Analysis: 3. Demonstrated High-Throughput Performance\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Directly translates to lower cost-per-sample and faster turnaround times, which drives adoption in large translational studies, enabling larger studies and higher return-of-investment for core facilities.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e \u003cstrong\u003eYes\u003c\/strong\u003e. The ability to process over $\\mathbf{6.2}$ million cells and $\\mathbf{438}$ million transcripts on a single flow cell is a high bar.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e \u003cstrong\u003eDifficult\u003c\/strong\u003e. Throughput is a function of the entire system (chemistry, imaging, fluidics), not just one component. The G4X Spatial Sequencer is capable of simultaneous direct RNA sequencing, targeted transcriptomics, proteomics and fluorescent H\u0026amp;E from FFPE tissues.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e \u003cstrong\u003eYes\u003c\/strong\u003e. Showcasing this data at AGBT and using it to drive pre-orders demonstrates they use performance to sell. Pre-orders for the G4X are open, and initial shipments are on track for June 2025.\u003c\/p\u003e\n\u003cp\u003eThe following table summarizes key performance and platform data points:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eContext\/Platform\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCells Processed\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$\\mathbf{6.2}$ million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSingle G4X flow cell (10 serial renal cell carcinoma FFPE sections)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTranscripts Measured\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$\\mathbf{438}$ million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSingle G4X flow cell (10 serial renal cell carcinoma FFPE sections)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eG4 Platform Price\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$\\mathbf{\\$295,000}$\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReduced price from $\\mathbf{\\$350,000}$\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eG4X Initial Shipments\u003c\/td\u003e\n\u003ctd\u003eJune 2025\u003c\/td\u003e\n\u003ctd\u003eOn track as of February 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe high-throughput capability supports broader research adoption through specific features:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eG4X enables simultaneous measurement of transcript, protein, and fH\u0026amp;E data within the same sample.\u003c\/li\u003e\n\u003cli\u003eThe platform supports advanced 3D multi-omic reconstruction and niche detection.\u003c\/li\u003e\n\u003cli\u003eThe G4X is positioned as an upgrade to the G4® Sequencing Platform.\u003c\/li\u003e\n\u003cli\u003eThe system's performance is being used to scale 3D spatial analyses in larger retrospective clinical cohorts.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e \u003cstrong\u003eSustained\u003c\/strong\u003e. If they maintain the lead in scale, it becomes a structural advantage for large research centers.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSingular Genomics Systems, Inc. (OMIC) - VRIO Analysis: 4. Integrated Multiomic Readout Capability\n\u003c\/h2\u003e\n\u003cp\u003eThe PX Integrated Solution combines single cell analysis, spatial analysis, genomics and proteomics in one integrated instrument providing a versatile multiomics solution.\u003c\/p\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eProvides researchers with richer, multimodal data (RNA, protein, morphology) from the same sample slice, simplifying correlation studies.\u003c\/p\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003e\u003cstrong\u003eYes\u003c\/strong\u003e. Integrating sequencing as a universal readout for genomics and proteomics in one instrument is a key feature of the PX\/G4X vision. The G4X Spatial Sequencer is capable of simultaneous direct RNA sequencing, targeted transcriptomics, proteomics and fluorescent H\u0026amp;E from formalin-fixed, paraffin-embedded (FFPE) tissues.\u003c\/p\u003e\n\u003cp\u003eThe G4X enables integrated spatial readouts of RNA, protein, and morphology from the same FFPE tissue section in a single run, delivering subcellular resolution and multimodal insight at scale.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFeature\u003c\/th\u003e\n\u003cth\u003eSpecification\/Metric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eThroughput (Max Samples\/Run)\u003c\/td\u003e\n\u003ctd\u003eX4 Flow Cell\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e128\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpatial Transcriptomics\u003c\/td\u003e\n\u003ctd\u003ePlex Level\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e500-Plex\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpatial Proteomics\u003c\/td\u003e\n\u003ctd\u003ePlex Level\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e18 Plex\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost Reduction\u003c\/td\u003e\n\u003ctd\u003eFold\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5-fold\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost per Sample\u003c\/td\u003e\n\u003ctd\u003eSpatial at Scale\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$240\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSingle Cell Cost\u003c\/td\u003e\n\u003ctd\u003ePer Cell\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.0008\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMultiomic Reconstruction (Example)\u003c\/td\u003e\n\u003ctd\u003eCells\/Transcripts\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6.2 million cells \/ 438 million transcripts\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe G4X is driving the cost of spatial from thousands of dollars per sample to hundreds, resulting in a \u003cstrong\u003e5-fold\u003c\/strong\u003e reduction in cost of spatial at scale. Data generated from a single G4X X2 flow cell included a 3D multiomic reconstruction of \u003cstrong\u003e10\u003c\/strong\u003e, 10x10 mm kidney cancer sections with \u003cstrong\u003e6.2 million cells\u003c\/strong\u003e and \u003cstrong\u003e438 million transcripts\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003e\u003cstrong\u003eDifficult\u003c\/strong\u003e. Requires deep engineering across multiple detection modalities to work seamlessly on one instrument. The G4X is expected to position Singular to be the only company worldwide to offer capabilities for tissue-based in situ spatial multiomics and NGS on the same instrument.\u003c\/p\u003e\n\u003cp\u003eThe company shipped the \u003cstrong\u003efirst G4X Early Access instrument\u003c\/strong\u003e in Q3 2024. Total G4 instruments shipped was \u003cstrong\u003e24\u003c\/strong\u003e by the end of FY23.\u003c\/p\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003e\u003cstrong\u003eYes\u003c\/strong\u003e. This capability is central to their mission to advance science and medicine by providing comprehensive information.\u003c\/p\u003e\n\u003cp\u003eThe company ended Q3 2024 with \u003cstrong\u003e$113.8 million\u003c\/strong\u003e in cash and investments.\u003c\/p\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003e\u003cstrong\u003eSustained\u003c\/strong\u003e. This integration creates a stickier ecosystem than single-function competitors.\u003c\/p\u003e\n\u003cp\u003eG4 runs now average above \u003cstrong\u003e90% bases ≥ Q30\u003c\/strong\u003e; raised specifications to \u003cstrong\u003e85% bases ≥ Q30\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSingular Genomics Systems, Inc. (OMIC) - VRIO Analysis: 5. Early Access\/Clinical Validation Network\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides crucial, real-world feedback and third-party validation from top-tier institutions like Beth Israel Deaconess Medical Center and Vanderbilt University Medical Center.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e \u003cstrong\u003eYes\u003c\/strong\u003e. Securing early access at leading centers before broad commercial launch is a sign of strong initial credibility.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e \u003cstrong\u003eEasy\u003c\/strong\u003e. Relationships can be built, but the quality of the initial partners is hard to replicate instantly.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e \u003cstrong\u003eYes\u003c\/strong\u003e. They are actively using feedback from these sites to refine the platform before the \u003cstrong\u003eJune 2025\u003c\/strong\u003e shipments.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e \u003cstrong\u003eTemporary\u003c\/strong\u003e. The initial validation is strong, but others will secure similar partnerships over time.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eKey Financial and Operational Metrics for OMIC:\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eDate\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.91M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs on \u003cstrong\u003eDec 31, 2023\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcquisition Price Per Share\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$20.00\u003c\/strong\u003e in cash\u003c\/td\u003e\n\u003ctd\u003eAcquisition by Deerfield, announced \u003cstrong\u003eDec 23, 2024\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShareholder Approval Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eFebruary 19, 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eApproval for Deerfield acquisition\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLatest Reported Employee Count\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e169\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs on \u003cstrong\u003eJun 30, 2021\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Capitalization (Pre-Acquisition\/Recent)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$50.17M\u003c\/strong\u003e \/ \u003cstrong\u003e$50.77M\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eRecent public data points\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003ePlatform and Institutional Context:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe product pipeline comprises two initial integrated solutions: the \u003cstrong\u003eG4 Integrated Solution\u003c\/strong\u003e (targeting the NGS market) and the \u003cstrong\u003ePX Integrated Solution\u003c\/strong\u003e (targeting single cell, spatial analysis, and proteomics markets).\u003c\/li\u003e\n\u003cli\u003eVanderbilt University Medical Center (VUMC) is involved in the Alliance for Genomic Discovery (AGD) initiative, which sequenced \u003cstrong\u003e250,000 whole genomes\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe AGD dataset is being made available to the alliance's \u003cstrong\u003eeight biopharma members\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company's transition to a private entity following the acquisition provides greater flexibility for business strategy advancement.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSingular Genomics Systems, Inc. (OMIC) - VRIO Analysis: 6. Private Ownership and Financial Backing\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe February 21, 2025 acquisition by Deerfield Management provided capital flexibility and removed the pressure of public market reporting. The transaction involved acquiring outstanding common shares for $20.00 per share in cash. \n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAcquisition Closing Date: \u003cstrong\u003eFebruary 21, 2025\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eCash Consideration Per Share: \u003cstrong\u003e$20.00\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003ePremium to Pre-Proposal Price: \u003cstrong\u003e254%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eYes. Being backed by a focused healthcare investor post-acquisition is a unique structure in late 2025.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eDifficult. The specific deal terms and the investor relationship are unique to Singular Genomics Systems.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eYes. The Board believes this transition enhances their business strategy, suggesting alignment for long-term R\u0026amp;D.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eSustained. The private structure allows them to weather the negative margins seen in Q3 2025 (e.g., 3,237.89% negative net margin).\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcquisition Price Per Share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$20.00\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcquisition Closing Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eFebruary 21, 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 Net Income\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-81.59 M USD\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLatest Reported Negative Net Margin (as of 2025-11-30)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-3,237.89%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eSingular Genomics Systems, Inc. (OMIC) - VRIO Analysis: 7. New Executive Leadership Focus\n\u003c\/h2\u003e\n\u003cp\u003eThe transition following the acquisition by Deerfield Management Company, L.P. on \u003cstrong\u003eFebruary 21, 2025\u003c\/strong\u003e, involved a significant shift in executive leadership, which is a key resource to evaluate under the VRIO framework.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eDate\/Detail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcquisition Price Per Share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$20.00\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCash for outstanding common stock not owned by Deerfield\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShareholder Approval Date\u003c\/td\u003e\n\u003ctd\u003eFebruary 19, 2025\u003c\/td\u003e\n\u003ctd\u003eApproval for the transaction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew Chief Executive Officer\u003c\/td\u003e\n\u003ctd\u003eJosh Stahl\u003c\/td\u003e\n\u003ctd\u003eAppointed post-acquisition\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompany Status Post-Close\u003c\/td\u003e\n\u003ctd\u003ePrivate Company\u003c\/td\u003e\n\u003ctd\u003eTrading suspended on Nasdaq; delisting requested\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrevious CEO Role Change\u003c\/td\u003e\n\u003ctd\u003eDrew Spaventa\u003c\/td\u003e\n\u003ctd\u003eContinues on Board and as Special Advisor to the CEO\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: The appointment of Josh Stahl as CEO post-acquisition signals a clear, potentially more agile, strategic direction focused on execution, leveraging the company's technology including the G4® Sequencing Platform and the upcoming G4X™ Spatial Sequencer.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: \u003cstrong\u003eNo\u003c\/strong\u003e. Leadership changes happen frequently, especially after M\u0026amp;A transactions finalized at \u003cstrong\u003e$20.00\u003c\/strong\u003e per share.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: \u003cstrong\u003eEasy\u003c\/strong\u003e. New leaders can be hired by any competitor.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: \u003cstrong\u003eYes\u003c\/strong\u003e. The new leadership is tasked with driving the strategy forward, making the transition itself an exploited resource, supported by Deerfield Management.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: \u003cstrong\u003eTemporary\u003c\/strong\u003e. Its value depends entirely on the new CEO’s execution over the next 12-18 months.\u003c\/p\u003e\n\u003cp\u003eKey leadership structure elements include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNew CEO: Josh Stahl, who also joined the Board of Directors.\u003c\/li\u003e\n\u003cli\u003eBoard Member: Jason Myers, also joined the Board.\u003c\/li\u003e\n\u003cli\u003eContinuing Role: Drew Spaventa remains on the Board and serves as a special advisor to the CEO.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSingular Genomics Systems, Inc. (OMIC) - VRIO Analysis: 8. Commercially Available G4 Platform Installed Base\n\u003c\/h2\u003e\n\u003cp\u003eThe G4 Platform installed base represents existing capital assets deployed in customer laboratories, forming a foundation for recurring consumable revenue and future ecosystem adoption.\u003c\/p\u003e\n\u003cp\u003eThe value proposition is quantified by the installed base size and the associated revenue generation:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ4 2022 (Shipments)\u003c\/th\u003e\n\u003cth\u003eQ3 2023 (Cumulative)\u003c\/th\u003e\n\u003cth\u003eQ4 2023 (Shipments)\u003c\/th\u003e\n\u003cth\u003eQ1 2024 (Cumulative)\u003c\/th\u003e\n\u003cth\u003eQ3 2024 (Shipments)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eG4 Systems Shipped (Quarterly)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e8\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCumulative G4 Installed Base\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e16\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e30\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQuarterly Revenue (Approx.)\u003c\/td\u003e\n\u003ctd\u003e$\\sim$\u003cstrong\u003e$700 thousand\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$\\sim$\u003cstrong\u003e$1.0 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe G4 instrument MSRP at its release was \u003cstrong\u003e$350,000\u003c\/strong\u003e. The platform supports data output up to \u003cstrong\u003e400 Gb\u003c\/strong\u003e per flow cell, with a maximum total output of up to \u003cstrong\u003e6.4 billion reads\u003c\/strong\u003e across all four flow cells in a single run.\u003c\/p\u003e\n\u003cp\u003eThe installed base provides a base for cross-selling consumables and potentially upgrading users to the G4X ecosystem.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eThe company recognized revenue of \u003cstrong\u003e$0.4 million\u003c\/strong\u003e in Q3 2024, primarily from consumables sales.\u003c\/li\u003e\n\u003cli\u003eThe company recognized revenue of \u003cstrong\u003e$0.4 million\u003c\/strong\u003e in Q1 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 id=\"rarity\"\u003eRarity: No. Other NGS companies have installed bases.\u003c\/h3\u003e\n\u003cp\u003eThe G4 Platform is commercially available, having launched in April 2022.\u003c\/p\u003e\n\u003ch3 id=\"imitability\"\u003eImitability: Easy. Competitors can sell instruments, though perhaps not with the same performance profile.\u003c\/h3\u003e\n\u003cp\u003eThe G4 offers a combination of speed and power, sequencing up to four human genomes in just \u003cstrong\u003e16-19 hours\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch3 id=\"organization\"\u003eOrganization: Yes. The G4 provides a foundation while the G4X ramps up, balancing near-term revenue with long-term bets.\u003c\/h3\u003e\n\u003cp\u003eThe company shipped \u003cstrong\u003etwo\u003c\/strong\u003e G4 systems in Q3 2024 and the first G4X Early Access instrument.\u003c\/p\u003e\n\u003ch3 id=\"competitive-advantage\"\u003eCompetitive Advantage: Temporary. The installed base is valuable but erodes without continuous innovation like the G4X.\u003c\/h3\u003e\n\u003cp\u003eThe company's total annual revenue as of December 31, 2023, was \u003cstrong\u003e$2.91M\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSingular Genomics Systems, Inc. (OMIC) - VRIO Analysis: 9. Financial Resilience Post-Acquisition\n\u003c\/h2\u003e\n\u003cp\u003eThe analysis below is based on publicly available financial data preceding the acquisition closing date of \u003cstrong\u003eFebruary 21, 2025\u003c\/strong\u003e, and the structure enabled by the transition to a private entity under Deerfield Management Company, L.P.\u003c\/p\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eThe ability to absorb significant quarterly losses, such as the reported GAAP EPS Loss of \u003cstrong\u003e(\\$6.72)\u003c\/strong\u003e for the quarter ending September 30, 2024 (Q3 2024), without immediate solvency risk, supported by a cash position of \u003cstrong\u003e\\$113.8 million\u003c\/strong\u003e as of September 30, 2024.\u003c\/p\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003e\u003cstrong\u003eYes\u003c\/strong\u003e. Many pre-revenue or early-revenue life science firms cannot sustain such negative performance metrics, including a Net Loss of \u003cstrong\u003e\\$16.8 million\u003c\/strong\u003e in Q3 2024 and a negative Trailing Twelve-Month Return on Equity of \u003cstrong\u003e57.87%\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003e\u003cstrong\u003eDifficult\u003c\/strong\u003e. Requires a deep-pocketed, patient owner like Deerfield Management, which acquired the company for \u003cstrong\u003e\\$20.00\u003c\/strong\u003e per share in cash.\u003c\/p\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003e\u003cstrong\u003eYes\u003c\/strong\u003e. The private structure, effective post-acquisition on \u003cstrong\u003eFebruary 21, 2025\u003c\/strong\u003e, directly enables this resilience, allowing focus on technology over short-term profitability.\u003c\/p\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003e\u003cstrong\u003eSustained\u003c\/strong\u003e. As long as Deerfield remains committed, this financial cushion is a major advantage over public peers, whose performance is often judged against quarterly revenue of only \u003cstrong\u003e\\$0.4 million\u003c\/strong\u003e (Q3 2024).\u003c\/p\u003e\n\u003cp\u003eKey Financial Metrics Pre-Acquisition (Q3 2024):\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003ePeriod\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$0.41 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGAAP EPS Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e(\\$6.72)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$16.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$17.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Position\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$113.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of Sep 30, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Profit\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e(\\$0.3 million)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e13-Week Cash Flow Projection Context (Incorporating Q3 2024 Revenue):\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eProjected Weekly Cash Outflow based on Q3 2024 Operating Expenses: $\\frac{\\$17.8 \\text{ million}}{13 \\text{ weeks}} \\approx \\mathbf{\\$1.37 \\text{ million per week}}$\u003c\/li\u003e\n\u003cli\u003eIncorporated Revenue for Projection Basis (Q3 2024): \u003cstrong\u003e\\$0.41 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eEstimated Runway based on Q3 2024 Burn Rate: $\\frac{\\$113.8 \\text{ million}}{\\$16.8 \\text{ million (Net Loss)}} \\approx \\mathbf{6.77 \\text{ quarters}}$ (Pre-Acquisition)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eCash Flow Projection Structure (Hypothetical for 13 Weeks Post-Q3 2024):\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek\u003c\/td\u003e\n\u003ctd\u003eBeginning Cash Balance\u003c\/td\u003e\n\u003ctd\u003eProjected Cash Inflow\u003c\/td\u003e\n\u003ctd\u003eProjected Cash Outflow\u003c\/td\u003e\n\u003ctd\u003eEnding Cash Balance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 1\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$113.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$0.01 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$1.37 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 2\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$0.01 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$1.37 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 3\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$0.01 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$1.37 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 4\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$0.01 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$1.37 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 5\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$0.01 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$1.37 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 6\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$0.01 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$1.37 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 7\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$0.01 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$1.37 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 8\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$0.01 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$1.37 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 9\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$0.01 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$1.37 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 10\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$0.01 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$1.37 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 11\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$0.01 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$1.37 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 12\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$0.01 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$1.37 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 13\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$0.01 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$1.37 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516223611029,"sku":"omic-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/omic-vrio-analysis.png?v=1740215399","url":"https:\/\/dcf-model.com\/fr\/products\/omic-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}